Search research articles
Contact Us
Filters
Showing results (321-330 of 386) with videos related to
Page
of 39
Sort By:
The Lancet. Oncology
|
July 23, 2013
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial
David I Quinn, Catherine M Tangen, Maha Hussain, et al.
European Urology Oncology
|
December 12, 2024
Digital Pathology-based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer
Mark C Markowski, Yi Ren, Meghan Tierney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2024
Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer
Susan Halabi, Akash Roy, Larysa Rydzewska, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 4, 2012
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer
Steve Y Cho, Kenneth L Gage, Ronnie C Mease, et al.
Cancer Research
|
October 19, 2001
A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy
T L DeWeese, H van der Poel, S Li, et al.
Annali Di Igiene : Medicina Preventiva E Di Comunita
|
August 5, 2015
Feasibility and reliability of a questionnaire for evaluation of the exposure to indoor and outdoor air pollutants, diet and physical activity in 6-8-year-old children
C Zani, F Donato, S Grioni, et al.
European Urology
|
February 25, 2018
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies
Gwenaelle Gravis, Jean-Marie Boher, Yu-Hui Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2018
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Christos E Kyriakopoulos, Yu-Hui Chen, Michael A Carducci, et al.
JAMA Oncology
|
August 22, 2024
Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial
Catherine H Marshall, Benjamin A Teply, Jiayun Lu, et al.
Cancer
|
December 17, 2013
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer
Walter M Stadler, David J Vaughn, Guru Sonpavde, et al.
Page
of 39
Search research articles
Search
Showing results (321-330 of 386) with videos related to
Sort By:
Page
of 39
The Lancet. Oncology
|
July 23, 2013
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial
David I Quinn, Catherine M Tangen, Maha Hussain, et al.
European Urology Oncology
|
December 12, 2024
Digital Pathology-based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer
Mark C Markowski, Yi Ren, Meghan Tierney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2024
Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer
Susan Halabi, Akash Roy, Larysa Rydzewska, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 4, 2012
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer
Steve Y Cho, Kenneth L Gage, Ronnie C Mease, et al.
Cancer Research
|
October 19, 2001
A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy
T L DeWeese, H van der Poel, S Li, et al.
Annali Di Igiene : Medicina Preventiva E Di Comunita
|
August 5, 2015
Feasibility and reliability of a questionnaire for evaluation of the exposure to indoor and outdoor air pollutants, diet and physical activity in 6-8-year-old children
C Zani, F Donato, S Grioni, et al.
European Urology
|
February 25, 2018
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies
Gwenaelle Gravis, Jean-Marie Boher, Yu-Hui Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2018
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Christos E Kyriakopoulos, Yu-Hui Chen, Michael A Carducci, et al.
JAMA Oncology
|
August 22, 2024
Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial
Catherine H Marshall, Benjamin A Teply, Jiayun Lu, et al.
Cancer
|
December 17, 2013
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer
Walter M Stadler, David J Vaughn, Guru Sonpavde, et al.
Page
of 39